Omeros (NASDAQ:OMER) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04), Fidelity Earnings reports. The business had revenue of $4.61 million for the quarter, compared to analyst estimates of $3.07 million. During the same period in the previous year, the business earned ($0.16) EPS.

Shares of NASDAQ OMER traded down $3.00 during trading on Friday, hitting $13.02. The stock had a trading volume of 5,656,225 shares, compared to its average volume of 613,109. Omeros has a 12 month low of $8.36 and a 12 month high of $27.00. The firm has a market cap of $793.47 million, a price-to-earnings ratio of -16.48 and a beta of 3.79.

A number of analysts have commented on OMER shares. BidaskClub upgraded shares of Omeros from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. HC Wainwright set a $34.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Wednesday, July 18th. Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, August 29th. ValuEngine upgraded shares of Omeros from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 24th. Finally, Maxim Group reiterated a “buy” rating and issued a $32.00 target price on shares of Omeros in a research note on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $27.56.

In other news, VP Marcia S. Kelbon sold 7,529 shares of the company’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the sale, the vice president now owns 227,645 shares in the company, valued at approximately $5,861,858.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Omeros (OMER) Announces Earnings Results” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: S&P 500 Index

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.